development of this paper was performed as an extension and during the course of the HEPL master study and adapted according to thesis guidelines.
conducted from the payer's perspective for example, the patients travel costs are excluded as well as indirect costs due to production losses. For example, this viewpoint is used in the study by Reeve et al. where only direct medical cost are considered (2) .
Societal perspective: a perspective from which an economic evaluation is conducted that takes into account all costs to society as a whole, regardless who incurs them. It includes all costs and effects that are relevant as seen from the viewpoint of society, including indirect costs caused by the disease under investigation, such as production losses. For example, this viewpoint is used in the study by Nuijten et al. where not only direct medical cost but also costs associated with asthma, non medical costs and long term indirect costs are taken into account(3).
Discounting: Economic concept to handle time-preference, using a method of calculation by which costs and benefits occurring at different moments in time can be compared.
Discounting converts the value of future costs and benefits into their present value to account for positive time preferences for benefits (preference for current benefits as compared to future benefits) and negative time preferences for costs (preference for future costs as compared to current costs).
Incremental cost-effectiveness ratio (ICER): is defined as the ratio of the change in costs of a therapeutic intervention (compared to the alternative, such as doing nothing or using the best available alternative treatment) to the change in effects of the intervention.
Introduction
RSV bronchiolitis is the most common cause of infant morbidity during the winter season and is associated with a large burden of disease and high costs. Most children are infected with RSV during the first year of life. A recent population-based study showed that 30-50% of all children require medical attention for RSV bronchiolitis in the first year of life (4) . RSV infection is worldwide the most common cause of infant morbidity during the winter season and is associated with a large burden of disease and high costs. Each year, 10-14% of all children below 1 year of age require medical care for RSV bronchiolitis in the Netherlands adding up to about 25,000 infants each year (5) . A total of 1,500-2,000 of these children are hospitalised with RSV bronchiolitis in the Netherlands annually, with corresponding mean hospitalisation costs of € 3,000-4,000 per patient (6) (7) (8) .
The disease typically begins with signs of common cold, followed after a few days by coughing, dyspnoea and an expiratory wheeze (9) . Hospitalization in Europe and the United
States is estimated to be 1-3%(10) of all infants aged less than 13 months. Of these hospitalized children, about 10% of infants require mechanical ventilation at a Paediatric Intensive Care Unit (11) (12) (13) . After the acute illness, approximately 50% of children with RSV bronchiolitis will develop recurrent episodes of wheeze up to school age which is associated with reduced health-related quality of life (14;15) . Although the burden of disease is considerable, RSV-associated mortality in healthy term infants is probably low, but published estimates vary between 0 and 8% (16) (17) (18) (19) .
Important risk factors for RSV bronchiolitis are prematurity with or without chronic lung disease, congenital heart disease, Down syndrome and immunodeficiencies (20) (21) (22) (23) . Longterm airway morbidity during childhood occurs in 30-70% of hospitalized infants with RSV LRTI, which is referred to as post-bronchiolitis wheeze. The clinical picture of postbronchiolitis wheeze is recurrent episodes of wheezing, generally associated with viral upper respiratory tract infection (14) . It has been shown that post-bronchiolitis wheeze is associated with decreased health-related quality of life over a broad range of domains, including lung, gastrointestinal tract and sleeping domain (24) .
The only effective intervention to prevent RSV bronchiolitis is passive immunoprophylaxis with palivizumab, a monoclonal antibody against the F-protein of RSV. However, this is costly and requires monthly intramuscular injections. Due to high costs RSV immunoprophylaxis is only registered for use in selected populations during the first year of life with the exception of children with chronic lung disease (CLD) on home oxygen (2 years).
The average medical cost of palivizumab prophylaxis at the recommended dose of 15 mg/kg is 4,600 Euro during a 5 month prophylaxis period per patient, which currently leads to a total of 14 million Euro for RSV prevention annually (online GIPdatabank). The efficacy of palivizumab depends on the risk groups and varies from 39 to 80% in chronic lung disease and late preterms, respectively (25;26) . The average medical cost of palivizumab prophylaxis at the recommended dose of 15 mg/kg is 4400 Euro during a 5 month prophylaxis period per patient (27) .
Due to these high costs, the cost-effectiveness of palivizumab is subject of vigorous debate (28;29) . Most countries, like The Netherlands, have therefore restricted this treatment to specific high risk groups, i.e. preterm infants born before 32 weeks gestational age and younger than 6 months at the start of the RSV season, children with hemodynamically significant congenital heart disease (CHD), and children with CLD.
However, even the cost-effectiveness studies performed within these high risk groups used different perspectives, outcomes (HAP, QALY or LYG), populations, follow-up, and extra risk factors. The objective of this study therefore is to systematically review the literature on the cost-effectiveness of palivizumab prophylaxis in the following subgroups: 1) preterm infants born before 32 weeks gestational age (WGA), 2) preterm infants born between 32 and 35 WGA, 3) children with CLD, and 4) children with CHD.
Methods

Search strategy
We searched Pubmed and EMBASE from inception to week 15 2012 and the latest versions of the DARE, NHS EED and HTA databases using the terms cost, cost-effectiveness, respiratory syncytial virus and palivizumab (see Appendix for the complete search syntax) to identify articles reporting on the cost-effectiveness of palivizumab. In addition, a reference and related article search was performed.
Study selection
We screened identified titles and abstracts without blinding to authorship or journal. 
Study quality
Two authors (MB, MR) independently assessed the quality of all included studies using Drummond's check-list for assessing economic evaluations (1) . Ten specific domains were addressed, i.e. research question, competing alternatives, effectiveness, relevant cost and consequences, cost and consequence measures, unit measures, values, discounting, incremental analysis, sensitivity analysis and overall considerations. By answering prespecified questions we reported the execution of the study and judged the quality for each domain. The original quality scores, between brackets, were adapted to Good (Yes), Acceptable (Yes) and Poor (No/Can't tell) to be able to make a further quality assessment possible for the quality score "Yes" in the original Drummond score model. The new quality scores for each domain was 1) good, 2) acceptable, or 3) poor or unclear. Disagreement was resolved by discussion (MB, MR).
Analyses
All ICER values were inflated to 2009 values using country specific inflation rates, and converted to Euro values using mean conversion rates for the currency in the year of publication with foreign exchange databases (30) (31) (32) (33) (34) (35) (36) .
To study the influence of some important factors we performed sensitivity analyses with these factors, i.e. hospitalisation rates, mortality rates and sponsoring, study year and country of origin. For the comparison analyses, only the ICER values for the preterm children born before 35 WGA are shown because the number of studies focusing on the CLD and CHD subgroup were too low. Because no internationally accepted threshold for cost-effectiveness is available no threshold was adopted but cost-effectiveness levels were derived from the conclusions of the authors in the selected papers.
Results
Study selection
Our search retrieved a total of 339 articles. A total of 19 articles were included in this review ( Figure 1 ). No additional studies were identified by checking the bibliographies of the selected studies. Main reasons to exclude studies were that the articles did not cover respiratory syncytial virus or palivizumab or because the articles did not include an economic evaluation. Other studies that were not included were studies about elderly and replicate studies. Figure 2 shows the results of the quality assessment according to Drummond's check-list for assessing economic evaluations. All studies performed incremental analysis as this was an inclusion criterion. In 3 out of 19 studies (16%) the research question was not accurately described. In two studies (10%) the effectiveness of palivizumab was not adequately covered.
Study quality
Different cost and consequences were well described by most studies (69%). Only three studies (16%) did not use discounting, and two other studies did not describe it properly. 
Effectiveness
Eleven studies derived the clinical effectiveness of palivizumab from the previously performed phase III trials (25;26) . For preterm children, children with CHD and children with CLD they reported a reduction of the hospitalisation rate of 78%, 45% and 39% with palivizumab treatment versus no-prophylaxis, respectively. The effectiveness used in the other 8 studies was based on longitudinal birth cohort studies.
Costs
Nine studies did only report on direct costs associated with respiratory syncytial virus infection. The other nine studies reported on both direct and indirect costs.
Comparison of subgroups
Figure 3a-d and Table 4 . Summary of study characteristics of the systematic review of economic evaluations of palivizumab for the subgroup of children with congenital heart disease (CHD)
Sensitivity analyses
The results of our sensitivity analyses are shown in figures 4-9. Figure 4 shows the relation between the hospitalisation rate and the cost-effectiveness for the subgroup of children born before 32 WGA and children born between 32 and 35 WGA. Studies adopting an efficacy rate of approximately 80% for prophylactic treatment tend to be more cost-effective than studies using an efficacy rate of 55% as derived from the IMpact trial (25) . Figure 5 shows the relation between the mortality rate and cost-effectiveness. The mortality rates for children hospitalized with RSV infection varied from 0.5 to 8.1 %, and especially the latter rate has a tremendous effect on the cost-effectiveness. Studies with 8.1% mortality rate tend to be more cost-effective than studies using lower mortality rates. Figure 6 shows the relation between potential sponsoring by pharmaceutical companies and the costeffectiveness. Sponsored studies show a tendency to be more cost-effective. Figure 7 shows the relation between year of publication and cost-effectiveness. Economic evaluations from recent years tend to be more cost-effective. Figure 8 shows the geographic location of the various economic evaluations and the outcome of the analyses. The majority of studies performed in Europe appear to show more cost-effectiveness than the studies from America. Figure 7 . The relation between the cost-effectiveness of palivizumab and the year of publication for the subgroup of children born before 35 weeks gestational age. Figure 8 . The presented conclusion of cost-effectiveness studies of palivizumab shown per country for subgroup of children born before 35 weeks gestational age.
Discussion
The evidence regarding the cost-effectiveness of prophylactic treatment of RSV infection with palivizumab in subgroups varies considerably. This is in agreement with the results of other reviews (54) (55) (56) . Due to this high variability between studies and the broad ranges in all outcome measures conclusive recommendations are currently not possible.
The most important driver of cost-effectiveness seems the mortality rate, and even the other variations associated with cost-effectiveness, can often be attributed to differences in mortality.
This is also reflected in sponsored studies, although we are not the first to describe the influence of industry sponsoring on cost-effectiveness.(57) For example, most of the sponsored studies used a high mortality rate and productivity losses of children within a life time horizon, which are also based on mortality. These high mortality rates have a large impact on cost-effectiveness when
ICERs are reported for LYGs or QALYs. Every percent increase in mortality will mean that more life years or QALYs are gained despite the cost of palivizumab. As a result, the cost-effectiveness ratio will be lower. A recent study from Denmark suggests that the mortality rate of RSV probably does not exceed 1% (58) . The high mortality rate used is based on the study of Sampalis, in which there was a high amount of children with sudden or otherwise unexplained death for which the causal relation with RSV infection has not been proven (59) . The European studies, which are the more recent studies, also generally use the higher mortality rate. The need for solid RSV mortality rates is evident and should be an important RSV research subject.
The major strength of our systematic review is the diversity of the included studies with respect to localization, year of analysis and the subgroups studied. Nevertheless, some of our findings deserve further discussion. First, the included studies reported LYG, QALY or HAP, which cannot be compared directly. Cost per HAP as even considered an inferior outcome measure compared to cost per LYG or QALY but we included it in our systematic review as morbidity and especially hospitalisation is a much bigger issue than mortality in RSV infection and thus regarding a highly relevant outcome. Second, some studies ((3;40;41;44;51) looked at different subgroups but used identical modelling data (both costs and effects), and are therefore not independent as suggested in the figures. Third, cost data for palivizumab are generally based on 5 doses of palivizumab and no drug wastage, but in daily practice it is not unusual that more doses are given and is there considerable drug wastage because of the limited time a vial is usable after opening (3 hours). The real cost will thus often be higher than reported in most papers, although vial sharing becomes increasingly used. Fourth, one of our inclusion criteria was the presence of an ICER as outcome measure. This created a possible selection bias and we might have missed important studies for which the ICER could be calculated. Fifth, as our quality analysis shows, there were differences in study quality. Some studies used data derived from small cohort studies as a measure of effectiveness of palivizumab. The associated cost-effectiveness ratios are therefore not based on the best available evidence. This should be taken into account when comparing these studies to cost-effectiveness studies with a better approach. The original quality scores of the Drummond
Critical appraisal criteria, between brackets, were adapted to Good (Yes), Acceptable (Yes) and Poor (No/Can't tell) to be able to make a further quality assessment possible for the quality score "Yes" in the original Drummond score model. The authors chose this approach because a high variability in quality in the "Yes" area. Although this provided additional insight in study quality we don't recommend further use of this approach as domains should either be appropriately discussed, i.e. "Yes", or not, i.e. "No"/"Can't tell".
Evidence derived from cost effectiveness studies is used to inform decisions about the reimbursement of medical interventions in an increasing number of countries. Cost-effectiveness and cost-utility thresholds have either been explicitly specified by authorities or can be implicitly determined from examining past reimbursement decisions. However, the use of thresholds is disputed and alternative approaches to assess the value of a health technology have been proposed, such as the fixed budget approach, fixed trade off approach and flexible trade off approach. Although an explicit threshold approach will not be end of equity discussions within and between countries it will certainly help increase transparancy of reimbursement decisions.
Currently, interpreting the results of cost effectiveness analysis can be problematic, making it difficult to decide whether to adopt an intervention. The threshold for adoption is thought to be somewhere between €20 000/QALY and €100 000/QALY, with thresholds of €50-60 000/QALY frequently proposed. Future RSV cost-effectiveness analyses should make use of country specific epidemiological cost and effectiveness data and describe all input data on both unit and value level. This demands both large cohort studies, accurate RSV related mortality estimates and attention for short and long term consequences with respect to morbidity and indirect costs of productivity losses of parents and future productivity losses of children. Also, to increase legitimacy and decrease potential bias, the analyses should be performed independent from the influence of pharmaceutical companies.
Conclusion
The cost-effectiveness of prophylactic treatment of RSV infection with palivizumab in subgroups varies importantly, and is certainly not always below the threshold. The cost-effectiveness is mainly affected by mortality rates of RSV infection. Future research should focus on the major uncertainties in cost-effectiveness, particularly RSV-related mortality rate.
